Personalized medicine - Trends in molecular diagnostics: Exponential growth expected in the next ten years

Molecular Diagnosis and Therapy

Volumn 15, Issue 1, 2011, Pages 53-55

  Hoggatt, Julie ^a  

^a Wolters Kluwer Pharma Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL TRIAL (TOPIC); DRUG COST; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACEUTICAL PREPARATIONS;

HEPATITIS C VIRUS;

EID: 79953784627     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11534880-000000000-00000     Document Type: Article

References (3)

1. Presidents Council of Advisors on Science and Technology. Priorities for personalized medicine [online]. Available from URL: http://www.white house.gov/files/documents/ostp/PCAST/pcast-report-v2.pdf [Accessed 2011 Feb 18]
2. Personalized Medicine Coalition. The case for personalized medicine.Washington, DC: Personalized Medicine Coalition, 2006 Nov
3. Hoggatt J. Personalized medicine: trends in molecular diagnostics. Exponential growth expected in the next ten years. inThought Research, 2011 Feb 9